Currently, there are no approved targeted therapies for the treatment of KRAS-mutated NSCLC, since KRAS targeting has proven pharmacologically challenging and is still considered an “undruggable” protein [9,10]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.